Functional Gastrointestinal Disorders (FGIDs), including Irritable Bowel Syndrome (IBS), represent a significant burden on global healthcare systems, affecting quality of life and long-term patient well-being. As a key theme of the Global Gastroenterology, Liver Diseases & Hepatology Conference & Industry Expo, this track focuses on advancing understanding, diagnosis, and management of functional GI conditions through innovation and collaboration.
The session will explore the evolving science behind the gut–brain axis, visceral hypersensitivity, microbiome alterations, psychosocial factors, and dietary influences in FGIDs and IBS. Experts will discuss novel diagnostic approaches, evidence-based therapies, digital health tools, and personalized treatment strategies aimed at improving patient outcomes.
In alignment with the conference’s mission, this track also emphasizes investment opportunities and industry partnerships, encouraging collaboration between clinicians, researchers, pharmaceutical and nutraceutical companies, digital health innovators, and healthcare investors. Through expert lectures, panel discussions, and interactive sessions, participants will gain insights into emerging therapies, clinical guidelines, market trends, and real-world applications shaping the future of functional GI care.
Join global leaders to drive innovation, foster partnerships, and transform the management of Functional GI Disorders and IBS worldwide.
Sub Topics: Epidemiology of Functional GI Disorders, Pathophysiology of IBS, Gut–Brain Axis Mechanisms, Role of the Microbiome in IBS, Visceral Hypersensitivity, Psychosocial Factors in FGIDs, Stress and Functional GI Disorders, Rome IV and Emerging Diagnostic Criteria, Biomarkers in Functional GI Disorders, Post-Infectious IBS, Dietary Triggers and IBS, Low-FODMAP Diet Strategies, Nutritional Interventions in FGIDs, Probiotics and Prebiotics in IBS, Psychogastroenterology, Cognitive Behavioral Therapy for IBS, Neuromodulators in Functional GI Disorders, Pharmacological Management of IBS, IBS-C, IBS-D and IBS-M Treatment Approaches, Functional Dyspepsia, Overlap Syndromes in FGIDs, Pediatric Functional GI Disorders, Gender Differences in IBS, Impact of Hormones on FGIDs, Digital Therapeutics for IBS, Telemedicine in Functional GI Care, Personalized Medicine in FGIDs, Patient-Reported Outcomes in IBS, Quality of Life Assessment, Non-Pharmacological Therapies, Complementary and Alternative Medicine in IBS, Role of Sleep in Functional GI Disorders, Inflammation and IBS, Motility Disorders and IBS, Functional Bloating and Abdominal Distension, Health Economics of IBS, Burden of Disease and Healthcare Utilization, Industry Innovations in FGIDs, Drug Development for Functional GI Disorders, Regulatory Pathways for IBS Therapies, Clinical Trials in FGIDs, AI and Data Analytics in GI Care, Investment Opportunities in Digestive Health, Industry–Academia Collaborations, Future Directions in Functional GI Disorders
Keynote Points:
Chronic, lifelong disease requiring continuous treatment and monitoring
Strong market demand for biologics, biosimilars, and advanced therapies
Growth of personalized and precision medicine approaches in IBD
Increasing use of real-world data, digital monitoring, and remote care
Expansion of infusion centers and specialty IBD clinics
High investment in R&D, clinical trials, and pipeline innovation
Collaboration opportunities across pharma, diagnostics, and digital health
Benefits:
High lifetime value per patient due to long-term treatment needs
Predictable and recurring revenue streams for pharma and service providers
Premium positioning through innovation and specialized expertise
Strong payer and healthcare system focus on improved outcomes
Opportunities for partnerships, patient support programs, and education
Alignment with value-based care and advanced GI disease management models
WhatsApp: https://wa.me/+971551792927
Email: info-ucg@utilitarianconferences.com